Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for Journey Medical (DERM) over the last 6 years, with Q3 2025 value amounting to $39.7 million.

  • Journey Medical's Total Current Liabilities rose 1914.62% to $39.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.7 million, marking a year-over-year increase of 1914.62%. This contributed to the annual value of $35.2 million for FY2024, which is 1598.6% down from last year.
  • As of Q3 2025, Journey Medical's Total Current Liabilities stood at $39.7 million, which was up 1914.62% from $40.5 million recorded in Q2 2025.
  • In the past 5 years, Journey Medical's Total Current Liabilities ranged from a high of $76.9 million in Q1 2023 and a low of $33.3 million during Q3 2024
  • Over the past 5 years, Journey Medical's median Total Current Liabilities value was $48.5 million (recorded in 2023), while the average stood at $50.4 million.
  • As far as peak fluctuations go, Journey Medical's Total Current Liabilities soared by 8393.5% in 2021, and later crashed by 4992.74% in 2024.
  • Over the past 5 years, Journey Medical's Total Current Liabilities (Quarter) stood at $51.6 million in 2021, then rose by 29.48% to $66.8 million in 2022, then tumbled by 37.35% to $41.9 million in 2023, then dropped by 15.99% to $35.2 million in 2024, then rose by 12.91% to $39.7 million in 2025.
  • Its last three reported values are $39.7 million in Q3 2025, $40.5 million for Q2 2025, and $40.2 million during Q1 2025.